1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

UK Regulatory Changes During A Brexit Transition Period – The Government Explains All

 
• By Ian Schofield

Guidance documents on the regulation of medicines in the UK during a Brexit transition period have been published by the government, covering areas like batch release, drug approvals, and the role of the UK MHRA in the EU regulatory system.

Changes ahead
The UK government is trying to explain what will happen to regulation during a Brexit transition period

The UK government has issued a number of guidance documents in an attempt to clarify what is likely to happen to life sciences regulation during any Brexit transition period following the UK’s departure from the EU at the end of March 2019.

The documents, which update and expand on the government’s earlier advice on the regulatory implications of Brexit, cover topics such...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

Project Orbis: Annual UK Approvals Down Since 2022, But MHRA Touts Advantages

 
• By Eliza Slawther

The UK MHRA has emphasized the merits of the Project Orbis scheme, which has resulted in 12 new drug approvals and 14 indication extensions in the country so far. However, overall annual approval figures were lower in 2023 and 2024 than in the years prior.

UK Must Pay ‘A Little Bit More, A Little Bit Earlier’ For Gene Therapies – CGT Catapult Chief

 
• By Eliza Slawther

If the UK is to become a top three country in the cell and gene therapy space, it must overcome the current political “stumbling block” around making changes that recognize the value of these therapies, Matthew Durdy, CEO of the Cell and Gene Therapy Catapult, tells the Pink Sheet.

Results Reporting: UK Registry To Offer More Flexibility Than US-Based ClinicalTrials.gov

 
• By Vibha Sharma

ISRCTN says its new system for reporting clinical trial results summaries will simplify compliance, and includes features to reduce data entry errors, improve accuracy, enhance accessibility and the reuse of trial results.

England Prioritizes SGLT-2s & GLP-1s In Diabetes Market Access ‘Shake Up’

 
• By Neena Brizmohun

Recommendations from the health technology assessment institute, NICE, reflect a strategic shift from treating type 2 diabetes to proactively preventing future complications of the condition.

More from Europe